Months after further shrinking its pipeline, Liminal BioSciences has accepted a buyout offer from its top shareholder, Structured Alpha LP, at a 135% premium from the biotech’s current share price.
A new year means new culls as the biotech industry continues to rightsize after a 2022 marked by sometimes glutenous clinical ambitions that couldn’t be financially maintained.
MALVERN, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing breakthrough gene therapies and vaccines, announced that it has signed a non-binding letter of intent (LOI) with Liminal BioSciences, Inc. a Canadian public company with shares listed on NASDAQ for the acquisition of their manufacturing site in Belleville, Ontario, for an undisclosed amount.